A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients with Advanced or Metastatic Breast Cancer

Study identifier:1839IL/0141

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients with Advanced or Metastatic Breast Cancer

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

gefitinib and fulvestrant

Sex

Female

Actual Enrollment

60

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 May 2004
Primary Completion Date: -
Study Completion Date: 01 Oct 2007

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria